Ministry of Food and Drug Safety Establishes Administrative Basis for Expedited Review

The Ministry of Food and Drug Safety announced on April 6, 2026, that it has revised and implemented the "Regulations on Product Approval and Review of Biological Products," with the main changes including establishing the basis for expedited review of biosimilars.


Biosimilar Approvals to Accelerate as Expedited Review Regulations Are Revised View original image

A biosimilar is a biological product that has been proven to be comparable in quality, as well as in non-clinical and clinical equivalence, to an already authorized product for manufacture, sale, or import.


This revision was carried out to provide administrative support for expedited approvals, such as adding biosimilars to the list of products eligible for fast-track review, following the reduction of the biosimilar approval period from the previous average of 406 days to 295 days starting this year.


The Ministry has also established a rapid change management system for biological products by allowing pre-market notification or post-market reporting (annual report) for manufacturing method changes that have only minor impact on quality, which previously required an approval amendment process.



The Ministry of Food and Drug Safety stated that this revision not only supports the growth of the biopharmaceutical industry but also rationalizes the approval system, and that it will continue to improve the system through proactive administrative support in the future.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing